Literature DB >> 24313919

Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: A case report.

Toshihiko Komai1, Hirofumi Shoda1, Kenichi Yamaguchi1, Keiichi Sakurai1, Mihoko Shibuya1, Kanae Kubo1, Toshiyuki Takahashi2, Keishi Fujio1, Kazuhiko Yamamoto1.   

Abstract

A 38-year-old woman with relapsing longitudinal extensive transverse myelitis and Sjogren's syndrome (SS) was admitted with lower extremity muscle weakness. Studies showed high serum titer of anti-aquaporin4 antibody and gadolinium-enhanced-MRI T1-weighted lesions within thoracic cord. Clinical findings suggested neuromyelitis optica-spectrum disorder (NMO-SD). High-dose corticosteroids, plasma exchange and cyclophosphamide were not effective. After starting tocilizumab, her neurological findings gradually improved. This report describes the first evidence to show tocilizumab could be effective for NMO-SD with SS.

Entities:  

Keywords:  Anti-aquaporin4 antibody; Neuromyelitis optica; Sjogren's syndrome; Tocilizumab; Transverse myelitis

Mesh:

Substances:

Year:  2013        PMID: 24313919     DOI: 10.3109/14397595.2013.861333

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  11 in total

1.  Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.

Authors:  Aurelien Justet; Sebastien Ottaviani; Philippe Dieudé; Camille Taillé
Journal:  BMJ Case Rep       Date:  2015-05-14

Review 2.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

Review 3.  Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.

Authors:  Vyanka Redenbaugh; Eoin P Flanagan
Journal:  Neurotherapeutics       Date:  2022-03-10       Impact factor: 6.088

Review 4.  What's new in neuromyelitis optica? A short review for the clinical neurologist.

Authors:  Daniel Whittam; Martin Wilson; Shahd Hamid; Geoff Keir; Maneesh Bhojak; Anu Jacob
Journal:  J Neurol       Date:  2017-03-13       Impact factor: 4.849

Review 5.  Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside.

Authors:  Wenli Zhu; Yaling Zhang; Zhen Wang; Ying Fu; Yaping Yan
Journal:  Neurosci Bull       Date:  2020-06-12       Impact factor: 5.203

6.  Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.

Authors:  Itay Lotan; Richard McGowan; Michael Levy
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

7.  Refractory Sjögren's syndrome myelopathy successfully treated with subcutaneous tocilizumab: A case report.

Authors:  Yuichi Ishikawa; Koto Hattori; Junichi Ishikawa; Michio Fujiwara; Yasuhiko Kita
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 8.  Immune Monitoring upon Treatment with Biologics in Sjögren's Syndrome: The What, Where, When, and How.

Authors:  Joyce J B C van Beers; Jan G M C Damoiseaux
Journal:  Biomolecules       Date:  2021-01-16

Review 9.  Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome.

Authors:  Amrita Srivastava; Helen P Makarenkova
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

Review 10.  Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation.

Authors:  Farzana Chowdhury; Anwar Tappuni; Michele Bombardieri
Journal:  Front Med (Lausanne)       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.